Holen Sie sich die Stockscreener-App
6.85
2.84%
-0.20
Schlusskurs vom Vortag:
$7.05
Offen:
$7.2
24-Stunden-Volumen:
1.47M
Relative Volume:
2.23
Marktkapitalisierung:
$187.64M
Einnahmen:
$675.00K
Nettoeinkommen (Verlust:
$-26.62M
KGV:
-4.3622
EPS:
-1.5703
Netto-Cashflow:
$-31.34M
1W Leistung:
-10.92%
1M Leistung:
-15.95%
6M Leistung:
+26.85%
1J Leistung:
+926.22%
1-Tages-Spanne:
$6.66
$7.331
1-Wochen-Bereich:
$6.66
$7.82
52-Wochen-Spanne:
$3.71
$8.74
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Firmenname
Unicycive Therapeutics Inc
Sektor
Branche
Telefon
650-384-0642
Adresse
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Compare UNCY vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
6.85 | 187.64M | 675.00K | -26.62M | -31.34M | -1.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | Guggenheim | Buy |
| 2024-04-04 | Eingeleitet | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Aktie (UNCY) Neueste Nachrichten
Unicycive Therapeutics StockThursday chart snapshot and trading picture - AD HOC NEWS
Unicycive Therapeutics Inc (UNCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Unicycive Therapeutics Inc (UNCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Unicycive Therapeutics Inc (UNCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Unicycive Therapeutics Inc (UNCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Unicycive Therapeutics Inc (UNCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Unicycive Therapeutics Inc (UNCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Unicycive Therapeutics Inc (UNCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Unicycive Therapeutics Inc (UNCY) Institutional Confidence - TradingKey
[EFFECT] Unicycive Therapeutics, Inc. SEC Filing - Stock Titan
Unicycive (NASDAQ: UNCY) CEO receives 762,200 restricted stock units - Stock Titan
Unicycive Therapeutics (UNCY) director receives sizeable new RSU awards - Stock Titan
Director Laumas receives new RSU awards at Unicycive (NASDAQ: UNCY) - Stock Titan
Executive at Unicycive (UNCY) granted 169,500 restricted stock units - Stock Titan
Unicycive Therapeutics (UNCY) CFO awarded 169,500 RSUs as stock compensation - Stock Titan
Unicycive Therapeutics (UNCY) EVP receives 169,500 RSU equity award - Stock Titan
Number of shareholders of Unicycive Therapeutics, Inc. – NASDAQ:UNCY - TradingView
UNCY Q1 2026 Earnings: Wider-Than-Expected Loss Amid No Revenue, Shares SlipEarnings Acceleration Picks - newsline.com
UNCY SEC FilingsUnicycive Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Will Unicycive's OLC Clear The FDA Hurdle And Become An Attractive New Option For Hyperphosphatemia? - RTTNews
Hyperphosphatemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Ardelyx, Sanofi, Takeda Pharma, Unicycive Therapeutics, Taisho Pharma, Alebund Pharma - Barchart.com
Hyperphosphatemia Market Unlocking New Revenue Opportunities - openPR.com
Unicycive Expands At-The-Market Equity Offering Program - The Globe and Mail
Unicycive Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Unicycive Therapeutics Raises ATM Offering of Shares - Moomoo
Unicycive (NASDAQ: UNCY) boosts ATM capacity, files $50M S-3 shelf - Stock Titan
Unicycive Therapeutics (UNCY) registers $150M shelf; $50M ATM with Guggenheim - Stock Titan
Unicycive Therapeutics director Gaurav Aggarwal resigns from board By Investing.com - Investing.com Australia
Unicycive shares edge up as biotech looks to June FDA meeting and analyst lifts target - Bez Kabli
Unicycive Therapeutics director Gaurav Aggarwal resigns from board - Investing.com
UNCY Q1 2026 Earnings: Pre‑Revenue Biotech Reports Wider‑Than‑Expected Loss, Stock Edges Higher - newsline.com
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Unicycive Therapeutics (UNCY) - The Globe and Mail
UNCY Maintained by Benchmark -- Price Target Raised to $18.00 - GuruFocus
Benchmark raises Unicycive Therapeutics price target on FDA review By Investing.com - Investing.com Canada
Interview: Unicycive’s CEO on Biotech Innovation vs. Payer Reality - NAVLIN DAILY
UNCY: Upcoming Virtual Meeting Announced for May 29 - GuruFocus
H.C. Wainwright reiterates Unicycive stock rating on manufacturing progress By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Unicycive stock rating on manufacturing progress - Investing.com
Unicycive Therapeutics (UNCY) Edges Higher as Stock Tests Key Resistance Near $7.46Wide Range Bar - newsline.com
Unicycive Therapeutics Inc. (UNCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Unicycive Therapeutics (UNCY) Surges 5.9% as Shares Test Key ResistancePairs Trade - Newser
Unicycive Therapeutics (UNCY) CEO receives 762,200 restricted stock units award - Stock Titan
Unicycive Therapeutics (UNCY) director granted 126,300 RSUs as equity pay - Stock Titan
Unicycive CEO left clinical medicine to develop kidney disease therapies - The Business Journals
Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside - Seeking Alpha
Unicycive (NASDAQ: UNCY) EVP receives 169,500 RSUs as stock award - Stock Titan
Unicycive (UNCY) EVP receives 169,500 RSUs vesting over 3 years - Stock Titan
Unicycive (UNCY) CFO receives 169,500 restricted stock units as equity pay - Stock Titan
Unicycive Therapeutics (UNCY) Drops -4.29% — Key Support at $7.41 2026-05-19Risk Analysis - Newser
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Unicycive Therapeutics (UNCY) price target decreased by 23.53% to 32.20 - MSN
Finanzdaten der Unicycive Therapeutics Inc-Aktie (UNCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):